IAVI’s Vaccine Design & Development Lab is on the move! We’re pleased to announce that this leading vaccine R&D lab will soon be joining the life sciences community at 95 Greene Street in Jersey City, NJ. Known as the DDL, this diverse group of scientists and researchers is responsible for designing IAVI’s emerging infectious disease vaccine candidates – one of which is now in Phase 2 clinical trials in West Africa. Learn more: https://lnkd.in/eTBWf-js #lifesciences #vaccines #research #globalhealth
IAVI
Research Services
New York, NY 34,334 followers
Translating science into global health impact.
About us
Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.
- Website
-
www.iavi.org
External link for IAVI
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1996
- Specialties
- AIDS vaccine, research and development, product development partnership, HIV/AIDS, vaccine development, global health, capacity strengthening, clinical trials, and scientific research
Locations
-
Primary
125 Broad St
9th Floor
New York, NY 10004, US
Employees at IAVI
Updates
-
We're thrilled that Sir Jeremy Farrar will be delivering the Keynote Address at this year's 7th #GlobForumTBVax. We look forward to reflecting on Dr. Farrar's unique perspective on the connections between scientific advancements, partnerships and resources, and what is required from a global to a community level to successfully develop and implement new TB vaccines. IAVI is honored to soon be welcoming delegates to the 7th Global Forum in Rio de Janeiro in October, in close collaboration with our fellow co-organizers Stop TB Partnership Working Group on New TB Vaccines, TuBerculosis Vaccine Initiative (TBVI), Ministério da Saúde, and REDE-TB - Rede Brasileira de Pesquisas em Tuberculose.
We're excited to announce that Sir Jeremy Farrar, Chief Scientist at the World Health Organization, will deliver the keynote address at the 7th #GlobalForumTBVax in October. Dr. Farrar's insights and broad expertise through his exceptional leadership, vision, and longstanding commitment to global health will set a solid foundation for the discussions that will take place throughout the 7th Global Forum. #7GFTBV 🔗 Explore our full program at bit.ly/7GFTBVprog
-
-
DISCOVERY, IAVI's monthly newsletter, is live today. We're covering reflections from #AIDS2024, exciting headlines featuring our #EIDs program, a Meet the Scientist podcast episode from our #TB team, and so much more. What's in store for our next edition? Subscribe to find out! 📣 www.iavi.org/subscribe
-
-
IAVI reposted this
Are you looking forward to the 7th #GlobalForumTBVax in October? Check out our program-at-a-glance for a taste of what to expect in our dynamic 3-day program, including: 📢 6 plenaries 🗣️ 4 oral abstract sessions 📋 6 discussion sessions Keep an eye out for more updates on our speakers! And don't forget to register by 15 August to take advantage of early bird rates. #7GFTBV 👉 Explore the program at bit.ly/7GFTBVprog
-
-
A new article in Devex highlights strides toward a vaccine for #Lassafever, a hemorrhagic fever that causes seasonal outbreaks across West Africa. No vaccine is currently available, and treatment is limited. Recently, IAVI and our partners began a Phase 2 clinical trial of IAVI's Lassa fever vaccine candidate in Nigeria, Liberia, and Ghana. This candidate uses the same vaccine vector technology as a licensed Ebola vaccine. IAVI is also utilizing this vector to develop vaccines for a range of zoonotic diseases, including Lassa, Marburg, and Ebola Sudan – all of which have the potential to cause outbreaks of international concern. Such outbreaks are increasing as a result of climate change. Learn more about Lassa and what our Head of EIDs, Swati Gupta, has to say about Lassa vaccine development: https://lnkd.in/eQsm9u9D CEPI (Coalition for Epidemic Preparedness Innovations) | HJF Medical Research International
How a new vaccine candidate could outpace Lassa fever's deadly grip
devex.com
-
IAVI reposted this
Are you a member of the global TB community? You’re invited to a 7th #GlobalForumTBVax community engagement webinar! Join us to learn about the 7th Global Forum and how you can support global advocacy efforts for #newTBvaccines, including the #7GFTBV Community Declaration. 📅 Wednesday, 14 August ⏰ 8-9am EST | 3-4pm CEST | 4-5pm EAT | 6:30-7:30pm IST |8-9pm WIB With breakout group discussions in English, French, Hindi, Indonesian, Kiswahili, Russian & Spanish! Register: https://lnkd.in/eQpyTKcT
-
-
2024 has become a turning point in the fight against #malaria. The very first malaria vaccines (RTS,S and R21) are being rolled out to children in sub-Saharan Africa, with the potential to save thousands of lives. "The vaccines — the first to target any human parasite — represent a feat of both scientific grit and fundraising ingenuity," writes STAT. In a special report, STAT highlights the 40-year quest to develop effective malaria vaccines and the researchers who made key breakthroughs possible. One of them is Ripley Ballou, IAVI's Chief Medical Officer, who previously helped lead the development of the RTS,S vaccine. Learn more about Dr. Ballou and the complicated history of malaria vaccines: https://lnkd.in/ekjSUPeA
Behind the malaria vaccines: A 40-year quest against one of humanity's biggest killers
https://www.statnews.com
-
IAVI reposted this
AIDS 2024 wrap-up
https://www.iavi.org
-
“As Africa’s most populated country, Nigeria is playing an important leadership role in advancing the development of a vaccine – one prioritised by the WHO, given Lassa’s potential to cause a public health emergency of international concern," said IAVI's Dr. Gaudensia Mutua. Our Lassa fever vaccine candidate is currently progressing through Phase 2 clinical trials in West Africa. Gavi, the Vaccine Alliance's #VaccinesWork has the full story: https://lnkd.in/gHnT8T6e CEPI (Coalition for Epidemic Preparedness Innovations) | HJF Medical Research International
Time to hope for a Lassa fever vaccine?
gavi.org
-
Last week at the 25th International AIDS Conference, many warned that the global HIV/AIDS response is at a critical inflection point. Newsworthy developments permeated the conference, from the recent Phase 3 lenacapavir results to UNAIDS' newest global HIV/AIDS statistics. Several imperatives emerged from key sessions — ensuring new prevention options are affordable and accessible, plus why we still need an HIV vaccine. “Despite massive progress, we still have a major challenge,” noted Peter Piot, a former International AIDS Society president who is now a professor of global health. What's our path forward? Hear from the experts in today's IAVI Report, featuring reflections from #AIDS2024 ➡️ https://lnkd.in/dNEv7NMs
Another inflection point in the HIV/AIDS response
https://www.iavi.org